Bioasis Technologies
Richmond
About Bioasis Technologies
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $8.9M
- Funding stage: IPO
- Last round: Post-IPO Debt (Jun 2021)
- Ticker: cve:BTI
- Website: bioasis.us
- Phone: 1.203.390.7395
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/bioasis-technologies-162717 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.